Skip to main content

Advertisement

Table 2 Baseline characteristics for subjects who had available information on apolipoprotein E genotype

From: The effect of galantamine on brain atrophy rate in subjects with mild cognitive impairment is modified by apolipoprotein E genotype: post-hoc analysis of data from a randomized controlled trial

  Total (n = 274) APOE ϵ4 carriers (n = 129) APOE ϵ4 noncarriers (n = 145) P valuea
Age 68 (8.9) 69 (8.8) 68 (8.9) 0.76
Sex, female 48 53 44 0.16
Hypertension 44 36 50 0.02
Diabetes 8 8 9 0.72
Cholesterol 34 30 38 0.18
Smoking 8 6 10 0.29
ADAS-Cog/MCI 14 (7.0) 16 (7.4) 13 (6.2) 0.00
Whole brain (ml) 1,088 (122) 1,083 (110) 1,092 (132) 0.54
Hippocampal volume (ml) 5.91 (0.85) 5.83 (0.90) 5.98 (0.83) 0.17
  1. Data presented as means (standard deviation) or percentages. ADAS-Cog, Alzheimer’s Disease Assessment Scale – cognitive subscale; APOE, apolipoprotein E; MCI, mild cognitive impairment. aP values for differences in means or percentages between patients treated with placebo and those treated with galantamine.